Physician profile
Laura Hoffman
NPI 1487165742
$3,494.72
in general payments reported to CMS, 2019-2025
21 companies · $660 in 2025
The $660 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $816 · 2023: $761 · 2024: $1,118 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,012.36 | 2021-2025 | Dysport |
| Revance Therapeutics, INC. | $706.60 | 2024-2025 | Daxxify |
| Bsn Medical INC | $401.92 | 2022-2023 | |
| Merz North America, INC. | $324.23 | 2022 | |
| Abbvie INC. | $302.84 | 2022-2025 | |
| Allergan, INC. | $190.35 | 2022 | |
| Janssen Biotech, INC. | $117.91 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $95.25 | 2021-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $59.35 | 2024-2025 | |
| Amgen INC. | $44.29 | 2021-2023 | Blincyto, Kyprolis |
| Jazz Pharmaceuticals INC. | $43.34 | 2022-2023 | |
| Leo Pharma INC. | $31.12 | 2025 | Anzupgo |
| Celgene Corporation | $29.49 | 2021 | |
| Legend Biotech USA INC. | $22.42 | 2025 | Carvykti |
| Pfizer INC. | $20.75 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2022 | |
| Boston Scientific Corporation | $17.63 | 2024 | |
| Seagen INC. | $14.97 | 2021 | |
| Kite Pharma, INC. | $14.28 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2023 | |
| Glaxosmithkline, LLC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.